SLC1A5 and nonpapillary renal cell carcinoma: However, Xiao et al. [115] proposed a different view, reporting that FTO was upregulated in VHL-deficient ccRCC and promoted tumor metabolic reprogramming by targeting the glutamine transporter SLC1A5, contributing to the progression and lethality of ccRCC.